30Nov/20

Analysis of the ADCs Drugs Approved by FDA

November 30, 2020ReviewADC, CD30, FDA ADCsbioadc

Antibody-drug conjugate (ADC) has achieved great progress in the past decade. So far, ten ADC drugs have been approved by the FDA, of which five were approved in 2019 and 2020, andRead More…

13Oct/20

Design ADC with Creative Biolabs – Episode II

October 13, 2020Reviewadc Conjugate, ADC design, antibody of ADCbioadc

In the last blog, we learned that the main feature of ADC candidate target antigen is that it needs to be highly expressed on the surface of tumor cells and not expressedRead More…

17Sep/20

Design ADC with Creative Biolabs-Episode I

September 17, 2020ReviewADC design, DAR, tumor targetbioadc

As we all known, antibody-drug conjugate (ADC) is a drug obtained by chemical conjuagtion of antibody, linker and cytotoxin. Compared with simple monoclonal antibodies, ADC has better targeting and more efficient killingRead More…

17Sep/20

Blockbuster Deal for ADC: Merck Sharp & Dohme and Seattle Genetics Reach a $4.5 Billion Partnership

September 17, 2020NewsADC, HER2, ladiratuzumab vedotin, LIV-1, Trop-2bioadc

On September 13, 2020, Gilead announced that it would acquire Immunomedics, whose core product is Trop-2 ADC drug Trodelvy, for more than $20 billion. On September 14, 2020, Merck Sharp & DohmeRead More…

17Sep/20

Big Deal: Gilead Acquired Immunomedics for Nearly $20 Billion to Get Hot ADC Drugs

September 17, 2020NewsADC, breast cancer, Trop-2, trophoblast surface antigen 2bioadc

On Sept. 12, the Wall Street Journal reported that Gilead was reaching an acquisition agreement of more than $20 billion with Immunomedics to expand its oncology product pipeline, including trodelvy (sacituzumab govitecan),Read More…

20Aug/20

Medical Missile-ADC Drug-Will Take-Off

August 20, 2020News, UncategorizedADC, ADC development, ADC linkers, ADC toxinsbioadc

Recently, AstraZeneca reached a global development and commercialization agreement of up to US $6 billion with the Daiichi Sankyo Company Limited for the development and commercialization of the antibody-drug conjugate (ADC). ThisRead More…

12Jun/19

A Noval ADC for DLBCL Get Accelerated Approval

June 12, 2019NewsADC, chemoimmunotherapy, DLBCLbioadc

Recently, the United States Food and Drug Administration announced the accelerated approval of the antibody-conjugate drug (ADC) Polivy (polatuzumab vedotin-piiq) for the treatment of refractory adult patients with diffuse large B-cell lymphomaRead More…

07May/19

New Clinical Development Model of Kadcyla approved for the treatment of early mammary cancer

May 7, 2019NewsDM1, Early mammary cancer, HER2, Kadcylabioadc

The United States FDA approved the extended indication of its antibody coupling drug Kadcyla (ado-trastuzumab emtansine) as a postoperative adjunctive therapy for early mammary cancer patients with positive HER2 and still residualRead More…

03Apr/19

BCMA targeted therapy! GSK antibody drug conjugates apply for sale at the end of the year

April 3, 2019Antibody-drug Conjugates ResearchADC, Auristatin F, BCMA, GSK2857916bioadc

British pharmaceutical company GlaxoSmithKline (GSK) recently announced the clinical study DREAMM -1 (NCT02064387) further positive data of experimental anti-B cell mature antigen (BCMA) antibody drug conjugate (ADC) GSK2857916 in the treatment ofRead More…

08Mar/19

ADC-Polatuzumab Vedotin targeting CD79b has been prioritized by FDA in the United States

March 8, 2019Antibody-drug Conjugates Research, NewsADC, CD79b, fda, Polatuzumab Vedotinbioadc

Roche recently announced that the Food and Drug Administration (FDA) has accepted the biological product licensing application (BLA) of the antibody drug conjugate (ADC) Polatuzumab Vedotin and granted priority review qualifications forRead More…